Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models

PloS One
Sofia H L FrostO Press

Abstract

Pretargeted radioimmunotherapy (PRIT) is a multi-step method of selectively delivering high doses of radiotherapy to tumor cells while minimizing exposure to surrounding tissues. Yttrium-90 (90Y) and lutetium-177 (177Lu) are two of the most promising beta-particle emitting radionuclides used for radioimmunotherapy, which despite having similar chemistries differ distinctly in terms of radiophysical features. These differences may have important consequences for the absorbed dose to tumors and normal organs. Whereas 90Y has been successfully applied in a number of preclinical and clinical radioimmunotherapy settings, there have been few published pretargeting studies with 177Lu. We therefore compared the therapeutic potential of targeting either 90Y or 177Lu to human B-cell lymphoma xenografts in mice. Parallel experiments evaluating the biodistribution, imaging, dosimetry, therapeutic efficacy, and toxicity were performed in female athymic nude mice bearing either Ramos (Burkitt lymphoma) or Granta (mantle cell lymphoma) xenografts, utilizing an anti-CD20 antibody-streptavidin conjugate (1F5-SA) and an 90Y- or 177Lu-labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-biotin second step reagent. The two radio...Continue Reading

References

May 1, 1990·International Journal of Radiation Oncology, Biology, Physics·J F Fowler
Jul 18, 1990·Journal of the National Cancer Institute·D ColcherJ Schlom
Oct 21, 1993·The New England Journal of Medicine·O W PressB Porter
Apr 13, 1999·European Journal of Nuclear Medicine·G PaganelliU Veronesi
Mar 4, 2000·Proceedings of the National Academy of Sciences of the United States of America·D B AxworthyA R Fritzberg
Jun 22, 2001·Critical Reviews in Oncology/hematology·R SteinD M Goldenberg
Oct 24, 2001·Acta Oncologica·P BernhardtG Skarnemark
Jan 20, 2005·Bioconjugate Chemistry·Kevin J HamblettPatrick S Stayton
Aug 24, 2005·Cancer Biotherapy & Radiopharmaceuticals·William H MillerWynn A Volkert
Nov 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Donald J BuchsbaumAlbert F LoBuglio
Dec 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David M GoldenbergJean-François Chatal
Jan 11, 2007·Cancer Research·Mikael PerssonJörgen Carlsson
Feb 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ajay K GopalOliver W Press
Apr 29, 2010·Cancer Biotherapy & Radiopharmaceuticals·Roland B WalterJohn M Pagel
Nov 6, 2010·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Rafke SchoffelenOtto C Boerman
Nov 13, 2010·European Journal of Nuclear Medicine and Molecular Imaging·Christof SeidlReingard Senekowitsch-Schmidtke
Mar 9, 2012·Advances in Hematology·Sabrina DonnouSylvain Fisson
Jan 9, 2013·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Damian WildMartyn E Caplin
Apr 11, 2013·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Flavio ForrerAndreas Lohri
Jul 15, 2015·Nuclear Instruments & Methods in Physics Research. Section A, Accelerators, Spectrometers, Detectors and Associated Equipment·Brian W MillerLars R Furenlid

❮ Previous
Next ❯

Citations

Aug 20, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Emily B EhlerdingWeibo Cai
Jun 9, 2016·Nuclear Medicine and Molecular Imaging·Jin Su Kim
Sep 5, 2019·Pharmaceutics·Marjolein VerhoevenSimone U Dalm
Aug 23, 2019·Pharmaceutics·Klaudia SiwowskaCristina Müller
Jan 9, 2019·Frontiers in Pharmacology·Guozheng Liu
Jun 2, 2017·Cancer Research·Shyril O'SteenOliver W Press
Oct 22, 2020·Molecular Cancer Therapeutics·Johnnie J OrozcoJohn M Pagel
Feb 26, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Elif HindieChristophe Champion
Jan 9, 2019·Bioconjugate Chemistry·Joseph LauXiaoyuan Chen
Mar 24, 2020·Molecular Pharmaceutics·Carolina A FerreiraWeibo Cai

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
xenograft
irradiate

Software Mentioned

CurveExpert
TableCurve2D
Systat

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.